Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simcere Teams Up Again With Bristol-Myers For Co-Development In China

This article was originally published in PharmAsia News

Executive Summary

After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.


Related Content

Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Singapore's ASLAN Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts